Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
VXRT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.29 - $1.07
Previous CloseN/A
Volume1.40M
Average Volume (3M)1.97M
Market Cap
$81.29M
Enterprise Value$122.37M
Total Cash (Recent Filing)$147.71M
Total Debt (Recent Filing)$6.04M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 20, 2025EPS Estimate
-0.1Last Dividend Ex-Date
Nov 09, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding228,208,280
10 Day Avg. Volume2,467,709
30 Day Avg. Volume1,968,589
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.00
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.26
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$3.00Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Vaxart News
PremiumCompany Announcements
Vaxart’s Earnings Call: Revenue Soars Amid COVID-19 Hurdles
PremiumCompany Announcements
Vaxart Reports 2024 Financial Results and Vaccine Progress
---
Bulls Say, Bears Say
Bulls Say
Cash FlowVXRT has a cash runway into 2026E, with recent financing and BARDA funding to support several clinical and regulatory milestones.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Trial ProgressThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Market CompetitionNorovirus is an attractive market with VXRT now leading the way, as there's currently no approved norovirus vaccine, making the opportunity highly attractive.
---
Ownership Overview
1.04% Insiders
5.34% Mutual Funds
5.90% Other Institutional Investors
83.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VXRT FAQ
What was Vaxart Inc’s price range in the past 12 months?
Vaxart Inc lowest stock price was $0.28 and its highest was $1.07 in the past 12 months.
What is Vaxart Inc’s market cap?
Vaxart Inc’s market cap is $81.29M.
When is Vaxart Inc’s upcoming earnings report date?
Vaxart Inc’s upcoming earnings report date is May 20, 2025 which is in 37 days.
How were Vaxart Inc’s earnings last quarter?
Vaxart Inc released its earnings results on Mar 20, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.06.
Is Vaxart Inc overvalued?
According to Wall Street analysts Vaxart Inc’s price is currently Undervalued.
Does Vaxart Inc pay dividends?
Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here
What is Vaxart Inc’s EPS estimate?
Vaxart Inc’s EPS estimate is -0.1.
How many shares outstanding does Vaxart Inc have?
Vaxart Inc has 228,208,280 shares outstanding.
What happened to Vaxart Inc’s price movement after its last earnings report?
Vaxart Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -8.772%.
Which hedge fund is a major shareholder of Vaxart Inc?
Currently, no hedge funds are holding shares in VXRT
---
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (733.33% Upside)
$3.00 (733.33% Upside)
Hedge Fund Trend
Increased
By 32.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.76%
12-Months-Change
Fundamentals
Return on Equity
-114.71%
Trailing 12-Months
Asset Growth
81.19%
Trailing 12-Months
Company Description
Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
---
VXRT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with significant progress in norovirus vaccine development and revenue increase, offset by challenges in the COVID-19 program due to the stop work order.Read More>---
VXRT Stock 12 Month Forecast
Average Price Target
$3.00
▲(733.33% Upside)
Technical Analysis
Best Analysts Covering VXRT
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-38.59%
reiterated a buy rating 18 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.59% per trade.
---